Pipeline
Pioneering Treg-Targeted Therapies
Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction:
Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.
Autoimmune Diseases
Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases
* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.
Pioneering Treg-Targeted Therapies
Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.
Autoimmune Diseases
Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases
* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.
Pioneering Treg-Targeted Therapies
Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.
Neurodegenerative Diseases
Autoimmune Diseases
Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases
* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.
